• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer

    3/14/22 7:00:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email

    NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today that the Company has appointed Robert Francomano as Chief Commercial Officer, effective immediately. Mr. Francomano brings significant and broad biopharmaceutical commercial leadership to SELLAS, including experience building and managing oncology product brands through all stages of commercialization, most recently as Chief Commercial Officer at Stemline Therapeutics until the completion and integration of its acquisition by the Menarini Group last year.

    "Robert joins our team with over two decades of experience working in the biopharmaceutical industry, with a proven track record of successfully transforming a company from clinical-stage to full commercialization," said Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. "Given the depth of his experience, we are confident that Robert will be an invaluable asset to our team, especially as our product pipeline, including our lead candidate, galinpepimut-S (GPS), continues to mature. We are pleased to welcome Robert to SELLAS as we look forward to delivering key milestones across our pipeline and cancer treatments to patients in need."

    Prior to joining SELLAS, Mr. Francomano served as Chief Commercial Officer at Stemline Therapeutics, where he led the transformation of that organization from a clinical-stage entity to a company with full commercial capabilities and infrastructure in both the United States and European Union. Before that, Mr. Francomano held several key roles within the oncology divisions at Baxalta, Pfizer, GlaxoSmithKline and AstraZeneca, with vast responsibilities that spanned the developmental continuum from asset discovery through patent expiry.

    "Joining SELLAS at such a pivotal moment in the Company's evolution will allow me to leverage my global commercialization experience to further SELLAS's mission of bringing lifesaving immunotherapeutic treatments to market for cancer patients around the world," added Mr. Francomano. "I look forward to working alongside the Company's highly talented and strong leadership team and to build a commercial organization to help bring novel therapies to cancer patients extending their lives."

    About SELLAS Life Sciences Group, Inc.

    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.

    For more information on SELLAS, please visit www.sellaslifesciences.com.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as "plan," "expect," "anticipate," "may," "might," "will," "should," "project," "believe," "estimate," "predict," "potential," "intend," or "continue" and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS, the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company's clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption "Risk Factors" in SELLAS' Annual Report on Form 10-K filed on March 23, 2021 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

    Investor Contact

    Allison Soss

    KCSA Strategic Communications

    Email: [email protected]

    Phone: 212.896.1267

    Media Contact

    Raquel Cona

    KCSA Strategic Communications

    Email: [email protected]

    Phone: 212.896.1276



    Primary Logo

    Get the next $SLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

      NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in TP53 mutated Acute Myeloid Leukemia (AML) cells are being presented in a poster session at the American Association for Cancer Research (AACR) taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. Patients with TP53–mutated AML continue to face extremely poor outcomes, even with intensive chemotherapy or the addition of stem cell transplantation. Precl

      4/28/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

      NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois. Poster presentation details: Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines. Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 P

      4/23/25 10:23:46 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

      - 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted 20% ORR - - Trial Continues with Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a br

      4/8/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

      SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      11/8/24 8:33:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by SELLAS Life Sciences Group Inc.

      SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      2/7/24 3:01:47 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

      2/16/21 10:08:07 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Financials

    Live finance-specific insights

    See more
    • SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

      NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer

      9/8/22 8:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

      NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon

      11/12/21 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

      Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran

      8/12/21 4:22:52 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

      7/21/21 11:28:03 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital initiated coverage on Solaris Resources with a new price target

      RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

      6/21/21 6:52:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.

      DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      4/23/25 4:32:18 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.

      DEF 14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      4/23/25 4:30:48 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      3/20/25 4:07:39 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO Burns John Thomas was granted 194,300 shares, increasing direct ownership by 185% to 299,062 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      1/14/25 5:34:56 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Stergiou Angelos M. was granted 500,900 shares, increasing direct ownership by 140% to 859,032 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      1/14/25 5:34:30 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Scheinberg David A was granted 12,500 shares, increasing direct ownership by 118% to 23,082 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      1/14/25 5:34:08 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Leadership Updates

    Live Leadership Updates

    See more
    • SELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs

      NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls (CMC) and Quality. He joins the Company's executive leadership team and is responsible for developing and executing regulatory strategies. Elnatan has extensive regulatory and CMC pharmaceutical industry experience in the areas of oncology, immunology, and hematological diseases. His career spans over 25

      1/5/23 8:30:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer

      NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today that the Company has appointed Robert Francomano as Chief Commercial Officer, effective immediately. Mr. Francomano brings significant and broad biopharmaceutical commercial leadership to SELLAS, including experience building and managing oncology product brands through all stages of commercialization, most recently as Chief Commercial Officer at Stemline Therapeutics until the completion and integration of its acquisition by

      3/14/22 7:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care